Last updated: February 23, 2026
What is the drug associated with NDC 00338-0117?
NDC 00338-0117 corresponds to Rituximab (brand name Rituxan). It is a monoclonal antibody used primarily to treat certain non-Hodgkin's lymphomas, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune conditions.
What is the current market size for Rituximab?
The Rituximab market has grown steadily over recent years. Key market data:
| Year |
Global Market Value (USD billions) |
CAGR (2017-2022) |
Major Drivers |
| 2022 |
7.5 |
8.2% |
Increasing adoption in autoimmune diseases, expanding indications, biosimilars entry |
| 2021 |
6.9 |
- |
|
| 2020 |
6.3 |
- |
|
The market is expected to reach approximately USD 9.5 billion by 2025, driven by an increase in autoimmune disorder prevalence and innovations in biosimilars.
What are the key competitors and biosimilar landscape?
Biosimilars of Rituximab have entered markets globally, affecting pricing and market share. Notable biosimilars include:
- Truxima (Celltrion)
- Ruxience (Sandoz)
- Riabni (Pfizer)
- Kixity (Mitsubishi Tanabe)
Biosimilar penetration varies by geography; in the U.S., biosimilars hold approximately 60% of the Rituximab market share as of 2022. European markets experience higher uptake (~75%).
How is the pricing structured?
Originator Drug (Rituxan)
- Average wholesale price (AWP) per 100 mg vial: USD 600–800
- Typical treatment dose: 375 mg/m² weekly for four weeks, then maintenance doses
- Treatment course cost: USD 30,000–USD 45,000, depending on dosage and indication
Biosimilars
- Prices are approximately 20–30% lower than originator
- Average wholesale prices per 100 mg vial: USD 420–USD 560
- Cost savings contribute to increased adoption and expanded patient access
Reimbursement policies
Reimbursement varies:
- U.S.: Medicaid, Medicare, and private insurers cover Rituximab with negotiated discounts
- Europe: Reimbursement levels fluctuate by country, with some reimbursing up to 80%
What are the projections for drug pricing?
Pricing pressure from biosimilars is expected to continue. Key trends:
- By 2025: Prices for biosimilars may decline an additional 15–25% due to increased competition and policy changes
- Originator price pressure: Maintains a downward trend of 5–10% annually in mature markets
Market share and pricing impact projections:
| Year |
Biosimilar Market Share |
Estimated Average Price (USD per 100 mg vial) |
Predicted Revenue (USD billions) |
| 2023 |
65% |
440–560 |
5.7 |
| 2024 |
70–75% |
420–540 |
4.9–5.3 |
| 2025 |
75–80% |
400–520 |
4.0–5.0 |
What are regulatory and policy influences?
- The U.S. FDA approved biosimilars for Rituximab starting in 2017 (e.g., Truxima)
- European Medicines Agency (EMA) approved multiple biosimilars since 2018
- Policy initiatives focus on increasing biosimilar uptake, which could accelerate price declines
Summary of risk factors impacting price and market
- Patent expiration: The original patent expired in 2016, opening the market for biosimilars
- Regulatory environment: Stringent approval processes can delay biosimilar entry
- Market acceptance: Physician and patient willingness to switch to biosimilars influences adoption rates
- Reimbursement policies: Incentivize biosimilar use, impacting pricing strategies
Key Takeaways
- The Rituximab market is projected to grow to USD 9.5 billion by 2025, driven by expanding indications and biosimilar competition.
- Originator drug prices are decreasing due to biosimilar entry, with a typical reduction of 20–30%.
- Biosimilars are capturing approximately 60–80% market share in mature markets, leading to continued price declines.
- Reimbursement policies significantly influence market share and pricing trends.
- Competition and regulatory trends will likely sustain price pressure through 2025 and beyond.
FAQs
Q1: How does biosimilar approval impact Rituximab prices?
Biosimilar approval introduces competition, resulting in price reductions of 20–30% and increased market share for biosimilars.
Q2: What geographic markets have the fastest biosimilar adoption?
European countries lead in biosimilar uptake, with 75% market share, followed by the U.S. with 60%.
Q3: What factors influence Rituximab's future pricing?
Market competition, regulatory policies, reimbursement strategies, and biosimilar acceptance influence pricing.
Q4: Are new Rituximab formulations expected to impact the market?
No significant new formulations are expected within the foreseeable future; current trends focus on biosimilar competition.
Q5: What is the total market value of Rituximab in 2023?
Estimates indicate approximately USD 7.0–7.4 billion, accounting for biosimilar market penetration and pricing trends.
References
- MarketsandMarkets. (2022). Monoclonal Antibodies Market by Drug Type, Application, and Region.
- IQVIA. (2022). Global Use of Medicines Report.
- U.S. Food and Drug Administration. (2017). Approval of First Biosimilar for Rituximab.
- European Medicines Agency. (2018). Biosimilar Medicines Published Data.
- Medicare.gov. (2023). Coverage policies for biologics.
